We are live on ! Find out more
DMK

DMK Pharmaceuticals Corporation Common Stock

Delisted

DMK was delisted on the 6th of February, 2024.

50 hedge funds and large institutions have $5.35M invested in DMK Pharmaceuticals Corporation Common Stock in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 11

2% less funds holding

Funds holding: 5150 (-1)

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

45% less capital invested

Capital invested by funds: $9.69M → $5.35M (-$4.34M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $24K

Holders
50
Holders Change
-1
Holders Change %
-1.96%
% of All Funds
1.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
10
Reduced
11
Closed
10
Calls
Puts
$24K
Net Calls
-$24K
Net Calls Change
+$100K
Name Holding Trade Value Shares
Change
Change in
Stake
LCM
51
Leisure Capital Management
California
-$29K -319 Closed
Citadel Advisors
52
Citadel Advisors
Florida
-$27K -297 Closed
Wolverine Trading
53
Wolverine Trading
Illinois
-$22K -245 Closed
CIBC Private Wealth Group
54
CIBC Private Wealth Group
Georgia
-$20K -214 Closed
BCM
55
BTR Capital Management
California
-$13K -143 Closed
TRCT
56
Tower Research Capital (TRC)
New York
-$1K -13 Closed
Simplex Trading
57
Simplex Trading
Illinois
-$862 -12 Closed
Barclays
58
Barclays
United Kingdom
+$144 +2 New

DMK Hedge Fund Activity: Q3 2019 in Review

50 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2019, worth a combined $5.35M — down 45% from $9.69M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of DMK and 9 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 10 added.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.48M. The largest seller was First Manhattan, exiting entirely with an estimated $1.81M sold.

  • 50 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2019, down from 51 in Q2 2019.
  • Funds reported $5.35M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2019, down 45% quarter-over-quarter.
  • 9 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2019 and 10 closed out, a net change of -1 holder.
  • The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2019 was Anson Funds Management, an estimated $1.48M added.
  • The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2019 was First Manhattan, an estimated $1.81M sold.

Based on aggregated 13F filings for Q3 2019.